Comparative Pharmacology
Head-to-head clinical analysis: TETRACYN versus TETRAMED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TETRACYN versus TETRAMED.
TETRACYN vs TETRAMED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the A site.
Tetracycline inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the ribosome.
250–500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 6–12 hours (administer slow IV).
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in normal renal function; prolonged to 18-30 hours in severe renal impairment (CrCl <30 mL/min); dosing adjustment required.
Terminal elimination half-life is 12–15 hours in adults with normal renal function; in renal impairment (CrCl <30 mL/min), half-life may extend to >30 hours, requiring dose adjustment.
Renal (glomerular filtration): 60% unchanged in urine; biliary/fecal: 40% as active drug and metabolites; enterohepatic recirculation occurs.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; minor metabolic clearance accounts for 10%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic